跳至主要内容
临床试验/CTRI/2025/11/098218
CTRI/2025/11/098218招募中3 期

A Prospective, Randomised, Placebo - controlled, Double blind trial to Evaluate The Safety and Efficacy of a Proprietary Ayurveda Supplement Glucose & Metabolic Support in The Management Of Type 2 Diabetes Mellitus And Pre-Diabetes

LYBL Healthcare Technology India Private Limited   Floor No.: 5th floor Building No./Flat No.: Plot no B-9 Name Of Premises/Building: ITL Twin Tower Road/Street: Shakurbasti Rs City/Town/Village: New Delhi District: North West Delhi State: Delhi PIN Code: 1100341 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2026年1月1日最近更新:

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
90
试验地点
1

研究概览

简要总结

Group A: 30 Diabetes Mellitus type 2 subjects with Oral Hypoglycemic Agent, Metformin 500 mg twice a day before meals and Placebo identical with Investigational product 1 tab three times a day after meals with warm water along with standard diet, lifestyle and yoga protocol.

Group B: 30 Diabetes Mellitus type 2 subjects with Oral Hypoglycemic Agent Metformin 500 mg twice a day before meals and Glucose and Metabolic support three times a day after meals with warm water along with standard diet, lifestyle and yoga protocol.

Group C: 30 Pre - Diabetes Mellitus type 2 subjects: Glucose and Metabolic support 1 tab twice a day after the meals with warm water with standard diet, lifestyle and yoga protocol.

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
Participant and Investigator Blinded

入排标准

年龄范围
20.00 Year(s) 至 75.00 Year(s)(—)
性别
All

入选标准

  • Diabetic Participants (Groups A & B): Newly diagnosed type 2 diabetes mellitus Diagnosed within 3 months of time HbA1c more than 6.5% and less than 9% Prediabetic Participants (Group C): Known pre-diabetics for more than 1 year HbA1c between 5.7% and 6.5% No systemic comorbidities like cardiovascular disease, renal impairment, or hepatic dysfunction.
  • No evidence of significant complications of diabetes (e.g., retinopathy, nephropathy, neuropathy).

排除标准

  • Previously diagnosed Type 1 or Type 2 DM on insulin treatment Secondary diabetes due to other conditions (e.g., pregnancy, Cushing’s syndrome, pancreatitis) Pregnant and lactating mother History of gestational diabetes Concurrent use of other Ayurvedic or herbal medications for diabetes during past 6 months Subjects who have completed participation in any other clinical trial during past 6 months.

研究者

发起方
LYBL Healthcare Technology India Private Limited   Floor No.: 5th floor Building No./Flat No.: Plot no B-9 Name Of Premises/Building: ITL Twin Tower Road/Street: Shakurbasti Rs City/Town/Village: New Delhi District: North West Delhi State: Delhi PIN Code: 110034
申办方类型
Pharmaceutical industry-Indian
责任方
Principal Investigator
主要研究者

Dr Keertan M S

KAHERs Shri B M Kanakanwadi Ayurveda Mahavidyalaya

研究点 (1)

Loading locations...

相似试验

Role of Ayurveda Medicine in treatment of Diabetes | 临床试验